News | Heart Valve Technology | February 28, 2017

FDA Panel Supports Approval for First TAVR Embolic Protection Device

Claret Medical Sentinel Cerebral Protection System (CPS), FDA, TAVR embolic protection, transcatheter aortic valve replacement (TAVR).

February 28, 2017 — A U.S. Food and Drug Administration (FDA) panel has recommended market clearance for the Claret Medical Sentinel Cerebral Protection System (CPS). The FDA’s Circulatory System Devices Panel reviewed the device last week, which if approved by the FDA would become the first embolic protection system for use with transcatheter aortic valve replacement (TAVR).

The American Association of Neurological Surgeons (AANS) and the Society of NeuroInterventional Surgery (SNIS) endorsed the need for the technology at the panel meeting. The groups were represented at the public hearing by Adnan Siddiqui, M.D., Ph.D., professor of neurological surgery at the University of Buffalo and chief medical officer at the Jacobs Institute. “The Sentinel device has shown its potential, across multiple trials, to filter and remove brain-borne debris safely, with very few vascular complications,” he explained.

The Sentinel CPS is the only device designed to protect the brain by capturing and removing debris dislodged during TAVR that would otherwise enter the cerebral circulation and increase the potential for stroke. A formal vote was not taken as the Sentinel CPS is a medium risk accessory device reviewed as a de novo application.

“The Sentinel device has shown its potential, across multiple trials, to filter and remove brain-borne debris safely, with very few vascular complications,” said Martin Leon, M.D., of Columbia University Medical Center/New York-Presbyterian Hospital, and chairman of the SENTINEL Clinical Steering Committee. “When we see the size and heterogeneity of the material captured, it is reassuring for me as a practicing TAVR implanter to know that it can be removed from the patient’s vasculature before it reaches the brain.“

Read the article “Study Shows Definitive Neuro Benefit to Using TAVR Embolic Protection.”

In the landmark SENTINEL pivotal trial, the primary safety endpoint of MACCE at 30 days was met, with reported MACCE in the protected Sentinel group at 7.3 percent, significantly lower than the pre-specified historical performance goal of 18.3 percent and the rate of 9.9 percent seen in the control arm. The stroke rate for Sentinel-protected patients was 5.6 percent versus 9.1 percent for unprotected patients. Importantly, the observed peri-procedural stroke rate – encompassing 72 hours’ post-procedure — was reduced by 63 percent, from 8.2 percent for unprotected patients to 3 percent for protected patients.

In the trial, device delivery and retrieval were accomplished safely and successfully in 99.6 percent of cases. The Sentinel access site complication rate was only 0.4 percent. The device captured and removed embolic debris in 99 percent of patients in the study, with one in four patients having more than 25 pieces of debris with a size greater than, or equal to, 0.5 millimeters captured in the filters.

A meta-analysis of five randomized controlled clinical trials examining cerebral protection in valve repair and replacement procedures across more than 625 patients was published in the Journal of the American College of Cardiology (JACC) in January. More than 80 percent of the patients (510 subjects) came from three of the five cited studies where Claret Medical’s dual-filter cerebral protection systems were used. These data demonstrate that the use of cerebral protection is associated with a greater than 40 percent lower risk of death or stroke after TAVR. The data corresponded to a rate of one death or stroke potentially being averted for every 22 patients treated with cerebral protection.

“We were extremely pleased with the near unanimous recommendation of the committee based on consideration of the totality of the clinical evidence that we have generated over the past six years. This strong support was based on the excellent safety profile and ability of the Sentinel CPS to reduce cerebral insults,” said Claret Medical President and Chief Executive Officer Azin Parhizgar, Ph.D. “The panel provided valuable feedback that will help define future study success criteria in the field of cerebral protection. We look forward to working collaboratively and diligently with the U.S. FDA in the coming weeks to ensure that we can bring the Sentinel technology to American physicians and their patients.”

The Sentinel CPS is the most-studied device in the field of TAVR cerebral protection, having been systematically evaluated in three randomized controlled trials involving more than 600 patients. More than 3,250 patients worldwide have been protected with the device to-date.

Watch the VIDEO “Defining the Need for TAVR Embolic Protection.”

Read the article “Delirium Significantly Associated With Brain Lesions in Patients Post-TAVR.”

Read the about the late-breaker trial at TCT 2016, “TAVR Embolic Protection Did Not Reduce Emboli Brain Lesions.”

For more information:

Related Content

Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Overlay Init